Human iNKT cell activation using glycolipids with altered glycosyl groups
First Claim
1. A method for augmenting an immunogenicity of an antigen in a subject in need thereof, comprising co-administering said antigen with an adjuvant composition comprising a compound having a structure of Formula (I):
1 Assignment
0 Petitions
Accused Products
Abstract
Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.
-
Citations
29 Claims
- 1. A method for augmenting an immunogenicity of an antigen in a subject in need thereof, comprising co-administering said antigen with an adjuvant composition comprising a compound having a structure of Formula (I):
-
14. A method for stimulating an immune response in a human subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of an immune adjuvant composition in a pharmaceutically acceptable carrier, wherein the composition comprises (i) a pharmaceutically acceptable excipient and (ii) a compound having a structure of Formula (I)
-
15. A method for elevating the level of invariant Natural Killer T (iNKT) cells production in a human subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the composition comprises (i) a pharmaceutically acceptable excipient, and (ii) a compound having a structure of formula (I)
- View Dependent Claims (16)
-
17. A method for stimulating production of one or more cytokines and/or one or more chemokines in a human subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the composition comprises a compound having a structure of Formula (I) in an amount sufficient to increase cytokine and/or chemokine production,
wherein Formula (I) has the structure of; - View Dependent Claims (18, 19, 20, 21, 22)
- administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the composition comprises a compound having a structure of Formula (I) in an amount sufficient to increase cytokine and/or chemokine production,
- 23. A method for augmenting the immune response by an antigen in a subject, the method comprising administering to the subject an effective amount of a vaccine comprising one or more antigens and an immunogenic amount of an adjuvant composition comprising (i) a pharmaceutically acceptable excipient, and (ii) a compound having a structure of Formula (I)
Specification